emjreviews.com21h
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
The EMBO Journal19h
LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...